Genprex (GNPX) Stock Price, News & Analysis

Company Overview

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Key Stats

• Today's Range: $0.33 to $0.36
• 50-Day Range: $0.33 to $1.82
• 52-Week Range: $0.28 to $15.60
• Volume: 80,099 shs
• Average Volume: 215,634 shs
• Market Capitalization: $735,909.40
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Genprex Stock Analysis - MarketRank™

Genprex scored higher than 77% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Genprex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Genprex has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Genprex are expected to grow in the coming year, from ($5.70) to ($2.71) per share.

Price to Book Value per Share Ratio

Genprex has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.56% of the float of Genprex has been sold short.

Short Interest Ratio / Days to Cover

Genprex has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Genprex has recently increased by 501.23%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genprex does not currently pay a dividend.

Dividend Growth

Genprex does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.78

Percentage of Shares Shorted

9.56% of the float of Genprex has been sold short.

Short Interest Ratio / Days to Cover

Genprex has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Genprex has recently increased by 501.23%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for GNPX on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genprex insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.54% of the stock of Genprex is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 14.05% of the stock of Genprex is held by institutions.

GNPX Stock Analysis - Frequently Asked Questions

How have GNPX shares performed this year?

Genprex's stock was trading at $9.20 at the start of the year. Since then, GNPX stock has decreased by 96.2% and is now trading at $0.3506.
View the best growth stocks for 2024 here.

How were Genprex's earnings last quarter?

Genprex, Inc. (NASDAQ:GNPX) released its quarterly earnings data on Friday, August, 9th. The company reported ($3.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.30) by $0.70.

When did Genprex's stock split?

Shares of Genprex reverse split before market open on Friday, February 2nd 2024. The 1-40 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Genprex?

Shares of GNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Genprex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Genprex investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX) and OPKO Health (OPK).

Company Calendar

• Last Earnings: 8/09/2024
• Today: 10/05/2024
• Next Earnings (Estimated): 11/12/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GNPX
• CUSIP: N/A
• CIK: 1595248
• Web: www.genprex.com
• Phone: (877) 774-4679
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $10.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +2,752.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-30,860,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -318.57%
• Return on Assets: -224.95%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.95
• Quick Ratio: 1.95

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.99 per share
• Price / Book: 0.07

Miscellaneous

• Outstanding Shares: 2,099,000
• Free Float: 1,857,000
• Market Cap: $735,909.40
• Optionable: No Data
• Beta: -0.59